NasdaqGM:WVEPharmaceuticals
Wave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 Study
Wave Life Sciences (WVE) recently announced positive results from its Phase 1b/2a RestorAATion-2 study of WVE-006, showing favorable safety and promising clinical implications in treating alpha-1 antitrypsin deficiency. During the last quarter, the company's share price saw a 4% increase, likely bolstered by these developments and its partnership with GSK for the WVE-006 commercialization. This positive momentum in the stock price reflects broader market trends, where the S&P 500 and Nasdaq...